DQDaniel John Quinlan

Daniel John Quinlan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel John Quinlan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • John William Eikelboom

    McMaster University

    4 shared publications
  • Alexander G. Turpie

    From the Thrombosis Service, Hamilton Health Sciences, General Division (J.W.E., A.G.T.), Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada (J.W.E., S.R.M., A.G.G., S.Y.); Department of Radiology, Kings College Hospital, London, UK (D.J.Q.); Population Health Research Institute, Hamilton General Hospital, Hamilton, Ontario, Canada (S.R.M., S.Y.); and Department of Cardiology, Craigavon Area Hospital, Northern Ireland, UK (I.B.M.).

    1 shared publication
  • Anita Mazzarol

    1 shared publication
  • Cheng Fang

    1 shared publication
  • D. Bergqvist

    Department of Surgical Sciences, Section of Vascular Surgery, Uppsala University Hospital, Uppsala, Sweden

    1 shared publication
  • Eleni Konstantatou

    1 shared publication

Latest Publications

  • Comparison of quantitative acoustic radiation force impulse imaging and 2D SWE of liver fibrosis in chronic liver disease

    by Cheng Fang, Eleni Konstantatou, Gibran Yusuf, Odyssefs Romanos, Daniel J Quinlan, Paul S Sidhu

  • Open Access

    Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty

    by Menno V. Huisman, Daniel J. Quinlan, Ola E. Dahl, Sam Schulman

    Background—: Dabigatran and rivaroxaban are novel oral anticoagulants approved for prevention of venous thromboembolism after hip or knee arthroplasty. However, information assessing clinically important efficacy and bleeding outcomes of these 2 new agents versus low-molecular-weight heparin (enoxaparin) is lacking. Methods and Results—: We separately pooled efficacy and safety data from 6 phase III randomized trials (18 405 participants) comparing equivalent durations of treatment with enoxaparin (40 mg once daily [od] or 30 mg twice daily) versus dabigatran (220 mg od) or versus rivaroxaban (10 mg od) after hip or knee arthroplasty. Odds ratios (OR) for individual outcomes were calculated for each trial and were pooled using the Mantel-Haenszel method. Compared with dabigatran, enoxaparin had a similar risk of symptomatic venous thromboembolism plus all-cause mortality (0.9% versus 1.1%; OR, 0.76; 95% confidence interval [CI], 0.44 to 1.31; I 2 =76%) and bleeding (5.0% versus 5.6%; OR, 0.90; 95% CI, 0.71 to 1.15; I 2 =0%). Compared with rivaroxaban, enoxaparin had a 2-fold higher risk of symptomatic venous thromboembolism plus all-cause mortality (1.2% versus 0.6%; OR, 2.04; 95% CI, 1.32 to 3.17; P 2 =0%) but demonstrated a significant lower risk of bleeding (2.5% versus 3.1%; OR, 0.79; 95% CI, 0.62 to 0.99; P =0.049; number needed to harm, 167; I 2 =0%). Conclusions—: In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding. Enoxaparin was less effective than rivaroxaban but had a lower risk of bleeding. These results may have important implications for the choice of prophylactic agent in major joint arthroplasty.


  • Open Access

    Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST Elevation Myocardial Infarction

    by Daniel J. Quinlan, John W. Eikelboom

    The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment (ExTRACT)–Thrombolysis in Myocardial Infarction (TIMI)-25 study1 demonstrated that the administration of enoxaparin sodium, 30 mg intravenously, followed by subcutaneous injections of 1 mg/kg twice daily (dose modified in patients 75 years or older), compared with intravenous unfractionated heparin (UFH), 60 U/kg bolus (maximum 4000 U), followed by 12 U/kg/h (initial maximum, 1000 U/h, and subsequently adjusted to maintain an activated partial thromboplastin time of 1.5-2.0 times the control value), reduced the risk of nonfatal reinfarction in patients with ST elevation myocardial infarction (STEMI) treated with thrombolysis. Because the ExTRACT-TIMI 25 study seems likely to be the last large trial evaluating the efficacy and safety of low-molecular-weight heparin (LMWH) in patients with STEMI, we added the results of this pivotal 20 000 patient trial to our meta-analysis published in 2005.2 Our updated literature search identified 1 additional study by Wang and colleagues3 published in 2006 involving 186 patients with STEMI who were randomized to receive parnaparin sodium or UFH; this study was also added to our meta-analysis.


  • Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction

    by John W. Eikelboom, Daniel J. Quinlan, Shamir R. Mehta, Alexander G. Turpie, Ian B. Menown, Salim Yusuf

    Background— There is uncertainty about the role of intravenous unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in patients with ST-elevation myocardial infarction (STEMI) treated with aspirin and thrombolysis. Methods and Results— We performed a meta-analysis of the randomized trials to assess the effect of UFH and LMWH on reinfarction, death, stroke, and bleeding. Fourteen trials involving a total of 25 280 patients were included (1239 comparing intravenous UFH versus placebo or no heparin; 16 943 comparing LMWH versus placebo; and 7098 comparing LMWH versus intravenous UFH). Intravenous UFH during hospitalization did not reduce reinfarction (3.5% versus 3.3%; odds ratio [OR], 1.08; 95% CI, 0.58 to 1.99) or death (4.8% versus 4.6%; OR, 1.04; 95% CI, 0.62 to 1.78) and did not increase major bleeding (4.2% versus 3.4%; OR, 1.21; 95% CI, 0.67 to 2.18) but increased minor bleeding (19.6% versus 12.5%; OR, 1.72; 95% CI, 1.22 to 2.43). During hospitalization/at 7 days, LMWH compared with placebo reduced the risk of reinfarction by approximately one quarter (1.6% versus 2.2%; OR, 0.72; 95% CI, 0.58 to 0.90; number needed to treat [NNT]=167) and death by &10% (7.8% versus 8.7%; OR, 0.90; 95% CI, 0.80 to 0.99; NNT=111) but increased major bleeding (1.1% versus 0.4%; OR, 2.70; 95% CI, 1.83 to 3.99; number needed to harm [NNH]=143) and intracranial bleeding (0.3% versus 0.1%; OR, 2.18; 95% CI, 1.07 to 4.52; NNH=500). The reduction in death with LMWH remained evident at 30 days. LMWH compared with UFH during hospitalization/at 7 days reduced reinfarction by &45% (3.0% versus 5.2%; OR, 0.57; 95% CI, 0.45 to 0.73; NNT=45), did not reduce death (4.8% versus 5.3%; OR, 0.92; 95% CI, 0.74 to 1.13) or increase major bleeding (3.3% versus 2.5%; OR, 1.30; 95% CI, 0.98 to 1.72), but increased minor bleeding (22.8% vs 19.4%; OR, 1.26; 95% CI, 1.12 to 1.43). The reduction in reinfarction remained evident at 30 days. Conclusions— In aspirin-treated patients with STEMI who are treated with thrombolysis, intravenous UFH has not been shown to prevent reinfarction or death. LMWH given for 4 to 8 days compared with placebo reduces reinfarction by approximately one quarter and death by &10% and when directly compared with UFH reduces reinfarction by almost one half. These data suggest that LMWH should be the preferred antithrombin in this setting.


    • 1 May 2004
      • Vol. 89  (5) , 586-93

    Thromboprophylaxis practice patterns in two Western Australian teaching hospitals.

    by John W Eikelboom, Anita Mazzarol, Daniel J Quinlan, Richard Beaver, James Williamson, Qilong Yi, Graeme J Hankey

    Evidence-based international guidelines recommend that all patients undergoing elective hip or knee arthroplasty receive thromboprophylaxis with low-molecular-weight heparin or adjusted-dose warfarin. Our objective was to determine what proportion of patients undergoing elective hip or knee arthroplasty actually receive recommended thromboprophylaxis according to international guidelines. We performed a prospective cohort study of 396 consecutive patients undergoing elective hip or knee arthroplasty between 1 May and 30 October, 2002. We collected baseline data, surgical and anesthetic details and recorded use of thromboprophylaxis and episodes of venous thromboembolism that occurred within 3 months of surgery. The mean age of the patients was 69.4 years (SD 11.5 years), and 62.2% (95% CI: 57.3 to 66.9%) were female. Hip arthroplasty was performed in 39.4% (34.6 to 44.2%) and knee arthroplasty in 57.1% (52.2 to 61.9%). Recommended thromboprophylaxis with low-molecular-weight heparin or warfarin was administered to 51.5% (46.6 to 56.4%). Objectively diagnosed venous thromboembolism occurred in 5.3% (3.3 to 8.0%) of patients; 3.5% (1.9 to 5.9%) of events occurred during hospitalization and 1.8% (0.7 to 3.6%) occurred following discharge from hospital. There was no significant reduction in the incidence of venous thromboembolism among patients treated with recommended thromboprophylaxis compared with those who did not but this is not a randomized comparison and is potentially confounded by the indication for treatment. Current thromboprophylaxis practice at our institutions falls substantially short of national and international guidelines. The reasons for low thromboprophylaxis use should be further explored and strategies for change implemented in order to optimize clinical practice.


    • 1 December 2003
      • Vol. 88  (12) , 1410-21

    Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.

    by Meyer Michel Samama, Ola E Dahl, Daniel J Quinlan, Patrick Mismetti, Nadia Rosencher

    Venous thromboembolism is a frequent and serious disorder influenced by numerous factors. As the first step in creating a tool to assess an individual patient's risk of venous thromboembolism, we carried out a literature review in order to quantify risk factors for venous thromboembolism. Risk factors were identified as being either predisposing, that is, those risks presented by a patient prior to hospital admission, or exposing, that is, those risks occurring when a patient is hospitalized for a certain medical condition or surgical procedure. Predisposing risk factors were classified with regard to the patients' characteristics (including general characteristics and inherent risk factors), and recent and chronic clinical conditions. The major predisposing factors among the patients' characteristics were age, hormonal therapy and personal history of venous thromboembolism, along with inherited coagulation factor abnormalities. Clinical situations associated with the highest risk of venous thromboembolism were recent surgery, hospitalization for medical conditions and immobilization, moderate to severe congestive heart failure, and malignancy. This literature review will assist in the development of a suitable risk assessment tool for aiding healthcare professionals to decide whether to employ thromboprophylaxis, and, if so, to select the appropriate type and duration of prophylaxis.


  • Variations in Lower Limb Venous Anatomy: Implications for US Diagnosis of Deep Vein Thrombosis

    by Daniel J. Quinlan, Raza Alikhan, Philip Gishen, Paul S. Sidhu

    To retrospectively review bilateral venograms free of thrombus to evaluate the frequency and types of variations seen in venous anatomy. A retrospective review of 404 bilateral (808 limbs) lower limb venograms obtained from medical patients participating in a thromboprophylaxis clinical trial and found to be free of thrombus was performed. Venograms were evaluated according to predetermined criteria for the presence of duplication of vessels and inter- and intraindividual variations in venous anatomy. Variations were assessed with analysis of variance and chi2 tests. Two vessels were seen in the popliteal fossa on 337 (42%) of 808 venograms, and 41 (5%) were true duplicated popliteal veins. There were 253 (31%) duplicated superficial femoral veins (SFVs), with 12 (1.5%) being complex duplicated systems. Of 265 duplicated SFVs, 138 (52%) began in the midthigh region and 80 (30%), in the adductor canal region. The duplicated vessel was medial to the main SFV in 122 (46%), lateral in 131 (49%), and both (ie, triplications) in 12 (4.5%). The length of the duplicated SFV ranged from 1 to 35 cm; 6-15 cm was the most common length in 162 (62%) SFVs. There was no significant association between the incidence of anatomic variations and age or sex (P >.1). The presence of multiple vessels in one leg was strongly correlated with the probability of occurrence in the other leg (P <.001). Variations in lower limb venous anatomy are common and have important implications for the US diagnosis of deep vein thrombosis.